DK0642344T3 - Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering. - Google Patents

Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering.

Info

Publication number
DK0642344T3
DK0642344T3 DK93910771.0T DK93910771T DK0642344T3 DK 0642344 T3 DK0642344 T3 DK 0642344T3 DK 93910771 T DK93910771 T DK 93910771T DK 0642344 T3 DK0642344 T3 DK 0642344T3
Authority
DK
Denmark
Prior art keywords
dry powder
pct
oral suspension
suspension formulation
stable dry
Prior art date
Application number
DK93910771.0T
Other languages
Danish (da)
English (en)
Inventor
Joel A Sequeira
Rebecca Galeos
Donald A Johnson
Lorraine Wearley
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0642344T3 publication Critical patent/DK0642344T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DK93910771.0T 1992-04-30 1993-04-30 Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering. DK0642344T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87688192A 1992-04-30 1992-04-30

Publications (1)

Publication Number Publication Date
DK0642344T3 true DK0642344T3 (da) 1997-07-07

Family

ID=25368763

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93910771.0T DK0642344T3 (da) 1992-04-30 1993-04-30 Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering.

Country Status (23)

Country Link
US (1) US5599557A (fi)
EP (1) EP0642344B1 (fi)
JP (1) JP3378004B2 (fi)
KR (1) KR100257803B1 (fi)
AT (1) ATE150310T1 (fi)
AU (1) AU674516B2 (fi)
CA (1) CA2134467A1 (fi)
CZ (1) CZ283428B6 (fi)
DE (1) DE69309052T2 (fi)
DK (1) DK0642344T3 (fi)
EE (1) EE03039B1 (fi)
ES (1) ES2099438T3 (fi)
FI (1) FI945081A (fi)
GR (1) GR3023516T3 (fi)
HK (1) HK1002407A1 (fi)
HU (1) HU215958B (fi)
NO (1) NO307594B1 (fi)
NZ (1) NZ252433A (fi)
PL (1) PL171630B1 (fi)
RU (1) RU2123863C1 (fi)
SK (1) SK279329B6 (fi)
UA (1) UA27899C2 (fi)
WO (1) WO1993021923A1 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007517039A (ja) * 2003-12-24 2007-06-28 アドバンシス ファーマスーティカル コーポレイション 変性放出製剤の吸収増強
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
JP5343002B2 (ja) * 2007-06-22 2013-11-13 株式会社カネカ 生理活性物質含有組成物
US20110123505A1 (en) * 2007-08-22 2011-05-26 Kaneka Corporation Method of producing reduced coenzyme q10 and method of stabilizing the same
WO2011139253A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
RU2550932C1 (ru) * 2014-03-18 2015-05-20 Александр Александрович Кролевец Способ получения нанокапсул цефалоспориновых антибиотиков в ксантановой камеди

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US4803082A (en) * 1987-10-28 1989-02-07 Warner-Lambert Company Flavor and sweetness enhancement delivery systems and method of preparation
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation

Also Published As

Publication number Publication date
HUT71226A (en) 1995-11-28
EP0642344B1 (en) 1997-03-19
EP0642344A1 (en) 1995-03-15
ES2099438T3 (es) 1997-05-16
DE69309052T2 (de) 1997-06-19
ATE150310T1 (de) 1997-04-15
AU674516B2 (en) 1997-01-02
CZ263694A3 (en) 1995-04-12
US5599557A (en) 1997-02-04
CA2134467A1 (en) 1993-11-11
UA27899C2 (uk) 2000-10-16
RU94046038A (ru) 1996-11-10
RU2123863C1 (ru) 1998-12-27
KR100257803B1 (en) 2000-08-01
PL171630B1 (pl) 1997-05-30
JP3378004B2 (ja) 2003-02-17
HK1002407A1 (en) 1998-08-21
JPH07506366A (ja) 1995-07-13
AU4115293A (en) 1993-11-29
GR3023516T3 (en) 1997-08-29
CZ283428B6 (cs) 1998-04-15
WO1993021923A1 (en) 1993-11-11
HU9403108D0 (en) 1995-02-28
KR950701224A (ko) 1995-03-23
SK131194A3 (en) 1995-07-11
HU215958B (hu) 1999-03-29
DE69309052D1 (de) 1997-04-24
SK279329B6 (sk) 1998-10-07
FI945081A0 (fi) 1994-10-28
FI945081A (fi) 1994-10-28
NO307594B1 (no) 2000-05-02
NO944113L (no) 1994-10-28
NZ252433A (en) 1996-07-26
NO944113D0 (no) 1994-10-28
EE03039B1 (et) 1997-10-15

Similar Documents

Publication Publication Date Title
DK0642344T3 (da) Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering.
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
ES8608864A1 (es) Un procedimiento para producir un preparado a modo de hojas
ATE192153T1 (de) Amino-imidazo (4,5-c) chinoline
DE69318503D1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
HUT37418A (en) Process for producing new 2,2'-imino-bis/ethanol/ derivatives and pharmaceutical compositions sontaining them as active agents
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
GR1002907B (el) Επικαλυμμενο δισκιο μηλεινικης τριμεβουτινης
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
MY115429A (en) Fenbendazole formulations
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
HUP0001773A2 (hu) Szubsztituált tetrahidropiridinszármazékok, eljárás előállításukra, továbbá a vegyületeket tartalmazó gyógyászati készítmények
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
DE3474024D1 (en) Contraceptive compositions based on esters of levo-norgestrel
ES8504774A1 (es) Procedimiento para preparar derivados de 2-piperacinil-quinazolina
PL308580A1 (en) Solid pharmaceutical composition for oral administration and method of preparing same
HU9302813D0 (en) Pharmaceutical compositions containing new benzimidazole derivatives and process for preparing the active ingredients
IL67400A0 (en) 3,7alpha-diazacyclohepta(j,k)fluorene derivatives,their preparation and pharmaceutical compositions containing them
EP0170024A3 (en) Use of 2-acylaminomethyl-1,4-benzodiazepine derivatives for the production of pharmaceutical compositions and process for the preparation for pharmaceutical compositions
ES8401483A1 (es) Procedimiento para preparar nuevas furobenzazepinas.
ITMI911653A1 (it) Derivati dell'eseridina ad attivita' anticolinesterasi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.